POSA128 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as a First-Line (1L) Maintenance Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma in Taiwan
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.271
https://www.valueinhealthjournal.com/article/S1098-3015(21)02066-0/fulltext
Title :
POSA128 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as a First-Line (1L) Maintenance Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma in Taiwan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02066-0&doi=10.1016/j.jval.2021.11.271
First page :
Section Title :
Open access? :
No
Section Order :
11043